<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256772</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0563</org_study_id>
    <nct_id>NCT04256772</nct_id>
  </id_info>
  <brief_title>Anti-IL5 and Other Biotherapies in Cystic Fibrosis</brief_title>
  <acronym>MAB-CF</acronym>
  <official_title>Anti-IL5 and Other Biotherapies in Cystic Fibrosis in French CF Centers : MAB-CF Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our project is to describe retrospectively and prospectively CF patients treated with&#xD;
      biotherapy in French CF centers.&#xD;
&#xD;
      Main objective: To describe the clinical and paraclinical course of CF patients before and&#xD;
      after treatment with anti-IL5 and other biotherapies since 2019.&#xD;
&#xD;
      Secondary objective: To describe adverse events potentially related to the biotherapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      •Background: ABPA and asthma associated with cystic fibrosis impact the CF course with a more&#xD;
      rapid decline in lung function.&#xD;
&#xD;
      Corticosteroid therapy can be harmful and must be avoid in CF to prevent diabetes,&#xD;
      osteoporomalacia or mycobacterium infections.&#xD;
&#xD;
      Monoclonal antibodies have the marketing authorization for severe uncontrolled asthma and, up&#xD;
      to now, some CF patients with ABPA or severe asthma and high plasma IgE levels benefit from&#xD;
      omalizumab.&#xD;
&#xD;
      Anti-Il5 agents are available since February 2019 and have demonstrated their efficacy in&#xD;
      severe and hypereosinophilic asthma control (plasma eos.&gt;300mmol/L).&#xD;
&#xD;
      Some patients with CF who have severe asthma or ABPA are still poorly controlled despite&#xD;
      Omalizumab with other treatments (steroids and/or azoles). Some of them have persistent&#xD;
      hypereosinophilia suggesting a possibility to treat with antiIL5 antibodies.&#xD;
&#xD;
      About 5% of patients have biotherapy treatment criteria, some have already received it,&#xD;
      others are elective to such treatment and will receive in the future.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Our project is to describe retrospectively and prospectively the clinical history of CF&#xD;
      patients eligible for biotherapy in French CF centers.&#xD;
&#xD;
      Main objective: To describe the clinical and paraclinical course of CF patients before and&#xD;
      after treatment with anti-IL5 and other biotherapies since 2019.&#xD;
&#xD;
      Secondary objective: To describe any adverse events potentially related to the biotherapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evolution</measure>
    <time_frame>1 day</time_frame>
    <description>Physical examination (height in centimeters, weight in kilograms, numerical scales in score, temperature in degrees, SaO2 in percentage).&#xD;
Defines the effectiveness of anti-inflammatory biotherapy in patients with cystic fibrosis To assess the effectiveness of anti-inflammatory biotherapy in patients with cystic fibrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry in liters or percentage evolution</measure>
    <time_frame>1 day</time_frame>
    <description>Spirometry in liters or percentage Defines the effectiveness of anti-inflammatory biotherapy in patients with cystic fibrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biology evolution</measure>
    <time_frame>1 day</time_frame>
    <description>Biology (leukocyte formula in 10^9/L, IgE tot, IgE spe, sputum microbiology) Defines the effectiveness of anti-inflammatory biotherapy in patients with cystic fibrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>concomitant therapy evolution</measure>
    <time_frame>1 day</time_frame>
    <description>concomitant therapy Defines the effectiveness of anti-inflammatory biotherapy in patients with cystic fibrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CFQR and SNOT22 evolution</measure>
    <time_frame>1 day</time_frame>
    <description>CFQR and SNOT22 questionnaires in score Defines the effectiveness of anti-inflammatory biotherapy in patients with cystic fibrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exacerbation evolution</measure>
    <time_frame>1 day</time_frame>
    <description>Defines the effectiveness of anti-inflammatory biotherapy in patients with cystic fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of any adverse event reported during biotherapy treatments</measure>
    <time_frame>1 day</time_frame>
    <description>Describe any adverse event potentially related to biotherapies. description of any adverse event reported during biotherapy treatments.</description>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Cystic Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        CF patients (2 known variants) with hypereosinophilia ≥ 300/µl and uncontrolled ABPA or&#xD;
        uncontrolled asthma, or failure of other biotherapy (intolerance, ineffectiveness)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Cystic fibrosis (2 known variants)&#xD;
&#xD;
          -  Age ≥ 6 years&#xD;
&#xD;
          -  Plasma hypereosinophilia ≥ 300/µl&#xD;
&#xD;
          -  Uncontrolled ABPA or uncontrolled asthma, or failure of other biotherapy (intolerance,&#xD;
             ineffectiveness)&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        - Refusal to participate in this research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael CHIRON, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CYSTIC FIBROSIS</keyword>
  <keyword>BIOTHERAPY</keyword>
  <keyword>ANTI-IL5</keyword>
  <keyword>BENRALIZUMAB</keyword>
  <keyword>APBA</keyword>
  <keyword>SEVERE ASTHMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

